LLS30
LLS30 is an anticancer agent. LLS30 suppresses MEK/ERK pathway. LLS30 has anti-cancer effects against ovarian cancer, prostate cancer, and malignant peripheral nerve sheath tumors. LLS30 shows synergistic anti-cancer effect with Enzalutamide (HY-70002) or Docetaxel (HY-B0011) [1].
Product Specifications
CAS Number
[2138367-58-3]
UNSPSC
12352005
Target
ERK; MEK
Related Pathways
MAPK/ERK Pathway; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(N)CC(C1=CC=C2N(CC3=CC=C(Cl)C(Cl)=C3)C(C4=CC=C(N(CCO)CCO)C=C4)=NC2=C1)NCC5=CC=C(Cl)C(Cl)=C5
Molecular Formula
C34H33Cl4N5O3
Molecular Weight
701.47
References & Citations
[1]Kit S. Lam, et al. Lls compounds for treatment of cancer. WO2017176767A1. WIPO (PCT) . 2017-04-04.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1107437-01 0.02 mg (E-Coli)
Recombinant Escherichia coli O81 Integration host factor subunit beta (ihfB)
Ask
View Details 
MBS1107437-02 0.1 mg (E-Coli)
Recombinant Escherichia coli O81 Integration host factor subunit beta (ihfB)
Ask
View Details 
MBS1107437-03 0.02 mg (Yeast)
Recombinant Escherichia coli O81 Integration host factor subunit beta (ihfB)
Ask
View Details MBS1107437-04 0.1 mg (Yeast)
Recombinant Escherichia coli O81 Integration host factor subunit beta (ihfB)
Ask
View Details MBS1107437-05 0.02 mg (Baculovirus)
Recombinant Escherichia coli O81 Integration host factor subunit beta (ihfB)
Ask
View Details MBS1107437-06 1 mg (E-Coli)
Recombinant Escherichia coli O81 Integration host factor subunit beta (ihfB)
Ask
View Details